CJC-1295 No DAC & Ipamorelin Mechanism: Research Application Comparison
Primary Mechanism GHRH receptor agonist. Extends pulse amplitude and duration by resisting DPP-4 degradation Ghrelin receptor (GHS-R1a) agonist. Triggers pulsatile GH secretion selectively Dual-pathway activation: GHRH primes secretory capacity while ghrelin r
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonist. Extends pulse amplitude and duration by resisting DPP-4 degradation
- Ghrelin receptor (GHS-R1a) agonist. Triggers pulsatile GH secretion selectively
- Dual-pathway activation: GHRH primes secretory capacity while ghrelin receptor triggers release
- Synergistic receptor-level interaction produces effects neither compound achieves alone
- Plasma Half-Life
- Approximately 30 minutes (vs 7 minutes for natural GHRH)
- Approximately 2 hours with GH peak at 15–30 minutes
- Overlapping pharmacokinetics during 90–120 minute pulse window
- Half-life alignment ensures peak receptor occupancy coincides with natural pulsatile rhythm
- IGF-1 Elevation
- Moderate elevation sustained 4–6 hours post-dose (20–40% above baseline in rodent models)
- Transient elevation 2–4 hours post-dose (15–30% above baseline)
- 3–5× greater IGF-1 AUC than either compound alone (University of Virginia data)
- Multiplicative effect indicates true synergy. Not just additive dosing
- Secondary Hormones
- Minimal ACTH/cortisol elevation (GHRH selectivity preserved)
- No ACTH, cortisol, or prolactin elevation (ghrelin receptor selectivity confirmed)
- Combined administration maintains selectivity. No cortisol spikes observed
- Receptor selectivity preserved in combination. Critical for research protocols isolating GH effects
- Receptor Downregulation Risk
- Low. Short half-life preserves pulsatile pattern and prevents continuous receptor occupancy
- Very low. Transient activation mimics endogenous ghrelin signaling
- Minimal when dosed 1–2×/day aligned with natural pulses
- Physiological pulsatility prevents negative feedback suppression that occurs with long-acting analogs